Singapore
· Delayed Price · Currency is SGD iX Biopharma Statistics
Total Valuation
iX Biopharma has a market cap or net worth of SGD 20.32 million. The enterprise value is 23.67 million.
| Market Cap | 20.32M |
| Enterprise Value | 23.67M |
Important Dates
The next estimated earnings date is Tuesday, February 4, 2025.
| Earnings Date | Feb 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.33% |
| Shares Change (QoQ) | +0.25% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 457.91M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 5.02 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.19 |
| EV / Sales | 3.97 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.47 |
Financial Position
The company has a current ratio of 0.89, with a Debt / Equity ratio of 1.20.
| Current Ratio | 0.89 |
| Quick Ratio | 0.65 |
| Debt / Equity | 1.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.76 |
| Interest Coverage | -16.96 |
Financial Efficiency
Return on equity (ROE) is -106.91% and return on invested capital (ROIC) is -31.51%.
| Return on Equity (ROE) | -106.91% |
| Return on Assets (ROA) | -23.69% |
| Return on Capital (ROIC) | -31.51% |
| Revenue Per Employee | 141,881 |
| Profits Per Employee | -257,000 |
| Employee Count | 42 |
| Asset Turnover | 0.30 |
| Inventory Turnover | 4.20 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -47.73% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -47.73% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.03 |
| Relative Strength Index (RSI) | 46.78 |
| Average Volume (20 Days) | 47,735 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, iX Biopharma had revenue of SGD 5.96 million and -10.79 million in losses. Loss per share was -0.01.
| Revenue | 5.96M |
| Gross Profit | 1.05M |
| Operating Income | -7.50M |
| Pretax Income | -9.99M |
| Net Income | -10.79M |
| EBITDA | -7.08M |
| EBIT | -7.50M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 1.84 million in cash and 5.20 million in debt, giving a net cash position of -3.36 million.
| Cash & Cash Equivalents | 1.84M |
| Total Debt | 5.20M |
| Net Cash | -3.36M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 4.34M |
| Book Value Per Share | 0.01 |
| Working Capital | -795,000 |
Cash Flow
In the last 12 months, operating cash flow was -6.55 million and capital expenditures -274,000, giving a free cash flow of -6.83 million.
| Operating Cash Flow | -6.55M |
| Capital Expenditures | -274,000 |
| Free Cash Flow | -6.83M |
| FCF Per Share | n/a |
Margins
Gross margin is 17.59%, with operating and profit margins of -125.78% and -181.14%.
| Gross Margin | 17.59% |
| Operating Margin | -125.78% |
| Pretax Margin | -167.56% |
| Profit Margin | -181.14% |
| EBITDA Margin | -118.88% |
| EBIT Margin | -125.78% |
| FCF Margin | n/a |
Dividends & Yields
iX Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.33% |
| Shareholder Yield | -0.33% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
iX Biopharma has an Altman Z-Score of -8.52. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.52 |
| Piotroski F-Score | n/a |